National Institutes of Health | National Institutes of Health Clinical Center | Critical Care Medicine Department

Research site

(Unclaimed)

Location

2C137A MSC 1662, Bethesda, Maryland, United States of America

Site insights

Top conditions

Top treatments

Androgen

Bosentan

Leniolisib

cyclophosphamide

ONC206

Ritonavir

STAR0602

sirolimus

doxorubicin

AZD6244

Parent organization

This site is a part of National Institutes of Health

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 48 total trials

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants with Advanced Solid Tumors (START-001)

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent...

Enrolling

Abdominal Neoplasm

Neoplasms by Site

Drug: STAR0602

A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

This study is researching an experimental drug called mibavademab. The study is focused on participants with GLD who have been on metreleptin treatme...

Enrolling

Generalized Lipodystrophy

Drug: mibavademab

Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome

The purpose of this is study is to evaluate the long-term safety of DCCR (diazoxide choline) extended-release tablets) in patients with Prader-Willi...

Active, not recruiting

Prader-Willi Syndrome

Drug: DCCR

Pediatric Patients Aged 1 to 6 Years With APDS

This is a 2-part, prospective, open-label, single arm, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic...

Active, not recruiting

APDS

Drug: Leniolisib

Pediatric Patients Aged 4 to 11 Years with APDS

This is a 2-part, prospective, open-label, single arm, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic...

Active, not recruiting

APDS

Drug: Leniolisib

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establi...

Enrolling

Glioblastoma

Glial Tumor

Drug: ONC206

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE™ CLL-1)

The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20). Epc...

Enrolling

Small Lymphocytic Lymphoma

Treatment-naïve High Risk Chronic Lymphocytic Leukemia

Drug: Lenalidomide

Drug: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone

SPEARHEAD-3 Pediatric Study

This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjec...

Enrolling

Osteosarcoma

Neuroblastoma (NBL)

Genetic: Afamitresgene autoleucel